Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth J Baum

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Nature Medicine|January 14, 2022
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)Michael J Koren, Patrick Maurice Moriarty, Seth J Baum, et al.
The Lancet. Digital Health|December 16, 2020
Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter dataKelly D Myers, Joshua W Knowles, David Staszak, et al.
European Heart Journal|January 13, 2022
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular riskJean-Claude Tardif, Ewa Karwatowska-Prokopczuk, Eric St Amour, et al.
Circulation. Cardiovascular Genetics|March 26, 2016
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH RegistryEmil M deGoma, Zahid S Ahmad, Emily C O'Brien, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
Journal of Clinical Lipidology|September 29, 2016
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registryZahid S Ahmad, Rolf L Andersen, Lars H Andersen, et al.
The New England Journal of Medicine|February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisStephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
Atherosclerosis|October 29, 2017
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registryStephen M Amrock, P Barton Duell, Thomas Knickelbine, et al.
Journal of the American Heart Association|April 29, 2023
Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH RegistryMarina Cuchel, Paul C Lee, Lisa C Hudgins, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Nature Medicine|January 14, 2022
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)Michael J Koren, Patrick Maurice Moriarty, Seth J Baum, et al.
The Lancet. Digital Health|December 16, 2020
Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter dataKelly D Myers, Joshua W Knowles, David Staszak, et al.
European Heart Journal|January 13, 2022
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular riskJean-Claude Tardif, Ewa Karwatowska-Prokopczuk, Eric St Amour, et al.
Circulation. Cardiovascular Genetics|March 26, 2016
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH RegistryEmil M deGoma, Zahid S Ahmad, Emily C O'Brien, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
Journal of Clinical Lipidology|September 29, 2016
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registryZahid S Ahmad, Rolf L Andersen, Lars H Andersen, et al.
The New England Journal of Medicine|February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisStephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
The Lancet. Gastroenterology & Hepatology|March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
Atherosclerosis|October 29, 2017
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registryStephen M Amrock, P Barton Duell, Thomas Knickelbine, et al.
Journal of the American Heart Association|April 29, 2023
Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH RegistryMarina Cuchel, Paul C Lee, Lisa C Hudgins, et al.
Pageof 7